Nohla Therapeutics just became the latest biotech startup to come out of the Fred Hutchinson Cancer Research Center. Like spinouts before it, Nohla is already well on its way to becoming one of Seattle’s rising… Read More
Arivale, the “scientific wellness” startup co-founded by genomics pioneer Lee Hood, has hired Grant Ries, the co-founder of big-data company BlueKai, as its first chief revenue officer — gearing up to work… Read More
Chad Cohen, who left the CFO gig at Zillow last month after nine years at the online real estate company, has landed a new gig at heavily-funded life sciences upstart Adaptive… Read More
Seattle is well known for making airplanes, coffee and software. But when it comes to cutting-edge biotechnology and health services, the region doesn’t always get top billing. That point of… Read More
The Life Sciences Discovery Fund — an investment vehicle used to fund early-stage biotechnology and life science research in the state of Washington — will be phased out over the… Read More
There’s a tsunami on the horizon, and it has cancer “running scared.” Those were the words from Fred Hutchinson Cancer Research president Dr. Gary Gilliland, who spoke Tuesday at the… Read More
Juno Therapeutics is no stranger to huge financing deals. The Seattle biotech company, which emerged on the scene just two years ago, raised $314 million in venture capital financing before… Read More
Shares of Seattle-based biotech startup Juno Therapeutics spiked more than 60 percent in after-hours trading on Monday after the company announced a $1 billion investment from Celgene. The 10-year “collaboration” will… Read More
Five years after coming to Seattle via its purchase of ZymoGenetics, drug giant Bristol-Myers Squibb is moving 40 Seattle-based research and development jobs to San Francisco, the company announced today. The… Read More
The groundbreaking for the new headquarters and R&D center of Juno Therapeutics at the Alexandria Center brings increased promise to the booming and fast-growing Seattle biotech industry. “We hope [this new building] will… Read More
The intersection of major research outposts like Fred Hutchinson Cancer Research Center and the University of Washington, plus a thriving tech community, make Seattle the perfect place for innovation in life… Read More
Shares of Seattle Genetics stumbled on Tuesday after the Bothell-based company announced a partnership to license the Antibody-Coupled T-cell Receptor (ACTR) technology from Cambridge, Mass.-based Unum Therapeutics. As part of the… Read More
The Fred Hutchinson Cancer Research Center helped spark a number of groundbreaking spin-off companies in recent years, from publicly-traded Juno Therapeutics to Blaze Biosciences which just this week announced the… Read More
Shares of Juno Therapeutics jumped more than six percent on Tuesday after the Seattle biotechnology company announced its acquisition of Waltham, Massachusetts-based X-BODY Inc. X-BODY is small, employing just nine… Read More
Enmi Kendall and Anya Schiess met more than 10 years ago while attending The Wharton School at the University of Pennsylvania. At the time, they both showed an interest in health… Read More
In the largest venture capital round in Washington state so far this year, Adaptive Biotechnologies has scored $195 million in fresh funding that the Seattle company said it will use… Read More
Every April, there was to be a show of symmetry in Washington state. This month, Big Tobacco made its annual delivery of millions of dollars to the state, a cash… Read More
—Telecommunications entrepreneur Vern Fotheringham has been named CEO of Leosat, an Arlington, Virginia-based company developing a constellation of low-earth orbit satellites. Fotheringham, a veteran of the telecom business who previously… Read More
Dendreon, the maker of the prostate cancer treatment Provenge, has been sold for $495 million to Valeant Pharmaceuticals International. The Wall Street Journal reports that the purchase price increased by… Read More
Dendreon, the once-promising Seattle biotechnology company that developed treatments for prostate cancer, will be sold to Quebec-based Valeant Pharmaceuticals International Inc. after no additional qualified bids emerged in the company’s bankruptcy… Read More
Juno Therapeutics, the fast-growing Seattle biotechnology company, today announced that it plans to open a new manufacturing facility in Bothell for its cell therapy products. The facility will open in… Read More
Adaptive Biotechnologies, a Seattle company that’s working on sequencing to profile T-cell and B-cell receptors, today announced that it is acquiring San Francisco-based Sequenta Inc. The company said in a press… Read More
Cerevast Therapeutics, a 5-year-old Redmond company that’s developing a novel approach for treating stroke patients with ultrasound, has raised $10 million in fresh funding, according to a filing with the SEC.… Read More
NanoString, a 12-year-old Seattle company whose tools help genetic researchers better analyze genes and molecules, is expanding its footprint in the South Lake Union neighborhood. The company announced today that… Read More
Danish drug maker Novo Nordisk announced plans today to open a new obesity research unit in Seattle, a move that had been previously reported earlier this month. The facility will attempt… Read More
Seattle’s biotech industry has been on an up-and-down roller coaster ride over the past 12 months, with layoffs and R&D center closures as well as huge financing rounds. Now, the… Read More
Seattle has been struck with some tough setbacks in the biotech community in the past few months, including the recent news that Amgen plans to close its R&D center along Elliott… Read More
Shares of Alder BioPharmaceuticals continue to fall after the company received notice from partner Bristol-Myers Squibb Company after the giant drug company determined that Alder’s experimental rheumatoid arthritis drug Clazakizumab “did not warrant… Read More
Dr. J. Wayne Cowens, the chief medical officer at Seattle-based NanoString Technologies, has died at the age of 67. “We are shocked and deeply saddened by the sudden loss of… Read More
Arch Venture Partners has operated longer than most venture capital firms by sticking close to its knitting. And now the 28-year-old firm has even more cash to continue funding early-stage… Read More